Related Experiment Video

Updated: Sep 14, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Novel androgen receptor inhibitors in prostate cancer: What do we know so far?

Francesca Rifaldi1, Paolo Pedrazzoli1, Anna Tortorella1

  • 1Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy; Radiation Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Critical Reviews in Oncology/Hematology
|July 19, 2025
PubMed

Insights

Androgen-receptor signaling inhibitors (ARSIs) are advancing prostate cancer (PC) treatment by targeting tumor growth pathways. This review explores current ARSI therapies, their clinical impact, and future directions in PC management.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Prostate cancer (PC) is a leading malignancy in males, often diagnosed at advanced stages.
  • Effective early screening methods for PC remain a significant clinical challenge.
  • Androgen signaling pathway inhibition is a cornerstone of PC therapy.

Purpose of the Study:

  • To provide an overview of current prostate cancer treatment options.
  • To focus on novel androgen-receptor signaling inhibitors (ARSIs) and their therapeutic implications.
  • To discuss the future developments in ARSI-based prostate cancer treatment.

Main Methods:

  • Systematic literature search of PubMed and Embase databases.
  • Keywords included 'prostate cancer', 'ARSI', 'androgen receptor inhibitors', 'enzalutamide', 'apalutamide', and 'Darolutamide'.
  • Review of original full-text articles published in English between 2019 and 2025.

Main Results:

  • Identified 185 potentially relevant articles, with 75 excluded based on initial screening.
  • Focused review on the role and efficacy of ARSIs in prostate cancer treatment.
  • Analysis of current clinical implications and future prospects of ARSIs.

Conclusions:

  • Androgen-receptor signaling inhibitors (ARSIs) represent a significant advancement in prostate cancer therapy.
  • ARSIs offer improved treatment outcomes by targeting key tumor growth mechanisms.
  • Ongoing research and development promise further refinements in ARSI-based treatment strategies for PC.
Keywords:
Androgen receptor inhibitorsProstate cancerTreatment

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.5K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K